Biotech ETF Provides Exposure to International Stocks


Aug. 6 2015, Updated 11:06 a.m. ET

ETF provides international exposure

The iShares Nasdaq Biotechnology ETF (IBB) has exposure to 14 international stocks in its portfolio, with a weight of 9.36%. For the week ended July 24, 2015, the average return of these shares was -2.13%, outperforming the benchmark index and the broader market SPDR S&P 500 ETF (SPY).

IBB fell by 5.03%, and SPY lost 2.80% over the same period. The above graph indicates the performance of all the ADRs (American Depository Receipts) within the ETF versus the benchmark, which is the fund itself.

Article continues below advertisement

Leaders and laggards

Among all the ADRs within IBB, Prothena (PRTA) outperformed all other stocks with a gain of 7.33%. The stock went up since RBC Capital Markets analysts were positive on Prothena’s Parkinson’s drug, which could hit the market in the first half of 2016.

PRTA has a weight of 0.18% in IBB’s portfolio. Endo International (ENDP), Qiagen N.V. (QGEN), and Horizon Pharma PLC (HZNP) ended flat to outperform the benchmark index.


More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.